Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 8/20 | 0.49 |
| ▸ | HTR2C | P28335 | 8/20 | 0.46 |
| ▸ | HTR2A | P28223 | 6/20 | 0.46 |
| ▸ | HTR2B | P41595 | 4/20 | 0.46 |
| ▸ | ICMT | O60725 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.35 |
| ▸ | HTR1D | P28221 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3803850 | 0.99 | HTR6 (0.48) | HTR6HTR2CHTR2AHTR2BICMT | |
| SCHEMBL13592836 | 0.92 | HTR6 (0.50) | HTR6HTR2CHTR2AHTR2BICMT | |
| Hydrochloric Acid SCHEMBL4397882 | 0.91 | HTR6 (0.49) | HTR6HTR2CHTR2AHTR2BICMT | |
| SCHEMBL13592841 | 0.88 | HTR6 (0.57) | HTR6HTR2CHTR2AHTR2BICMT | |
| Hydrochloric Acid SCHEMBL3803145 | 0.87 | HTR6 (0.56) | HTR6HTR2CHTR2AHTR2BICMT | |
| SCHEMBL3809146 | 0.87 | HTR6 (0.46) | HTR6HTR2CHTR2AHTR2BTAAR1 | |
| SCHEMBL13592837 | 0.82 | HTR2A (0.53) | HTR6HTR2CHTR2AHTR2BHTR1A | |
| SCHEMBL3804482 | 0.82 | HTR2C (0.57) | HTR6HTR2CHTR2AHTR2BICMT | |
| Hydrochloric Acid SCHEMBL4398477 | 0.81 | HTR2A (0.52) | HTR6HTR2CHTR2AHTR2BHTR1A | |
| SCHEMBL3791251 | 0.79 | HTR6 (0.41) | HTR6HTR2CHTR2AHTR2BICMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090318527-A1 | INDOLE COMPOUNDS AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-12-24 | — | — | US | disclosed |
| US-20090318527-A1 | INDOLE COMPOUNDS AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318527-A1 | INDOLE COMPOUNDS AND METHODS OF USE THEREOF | IDO1, IDO2, INMT | HTR6 8/4885HTR2C 30/4885HTR2A 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.